You are here

CAR-T

FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat

Fierce Biotech

Tue, 11/7/17 - 09:38 am

clinical trials

Novartis seeks European approval for cell therapy Kymriah

Reuters

Mon, 11/6/17 - 09:25 am

diffuse large B-cell lymphoma

acute lymphoblastic leukemia

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status

Endpoints

Wed, 11/1/17 - 06:52 pm

Juno Therapeutics

Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on

Endpoints

Tue, 10/31/17 - 09:38 am

diffuse large B-cell lymphoma

Gilead Slaps Mega-Price on Its Newly Approved CAR-T

Motley Fool

Fri, 10/20/17 - 09:04 am

Gilead Sciences

Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod

Fierce Pharma

Thu, 10/19/17 - 09:12 am

Gilead Sciences

non-Hodgkin's lymphoma

large B-cell lymphoma

4 Ways To Market CAR-T Therapies

Medical Marketing and Media

Mon, 10/16/17 - 09:43 pm

5 Game-Changing Cancer Drug Innovations Being Developed Right Now

Motley Fool

Thu, 10/12/17 - 10:45 am

cancer immunotherapies

T-cell receptors

TCR therapeutics

As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing

Fierce Pharma

Thu, 10/5/17 - 06:16 pm

performance-based pricing

Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work

Endpoints

Tue, 09/26/17 - 11:32 am

TCR-targeted drugs

clinical trials

Premium price for Novartis' CAR-T sparks pushback from top PBM

BioPharma Dive

Mon, 09/25/17 - 07:23 pm

Express Scripts

Express Scripts' Miller Backs New Pricing Models for CAR-T

BioCentury

Fri, 09/22/17 - 09:13 am

Express Scripts

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

Xtalks

Wed, 09/20/17 - 10:41 am

Juno Therapeutics

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

Xconomy

Tue, 09/19/17 - 08:43 am

Seattle Children's

pediatric cancer

Cell therapy emergence opens up new markets for shippers, logistic companies

BioPharma Dive

Fri, 09/8/17 - 09:41 am

New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph

Fierce Biotech

Tue, 09/5/17 - 11:10 am

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

Xconomy

Tue, 09/5/17 - 09:50 am

clinical trials

Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

Motley Fool

Tue, 09/5/17 - 09:28 am

Gilead Sciences

Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO

Endpoints

Mon, 09/4/17 - 10:13 am

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

Stat

Mon, 09/4/17 - 10:11 am

Pages